Clinical Trial

SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

Name: SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure — clinical trial record (NCT07311408)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SHR-2554

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment

Trial Details

NCT Number	NCT07311408
Lead Sponsor	Jingdong Zhang
Conditions	Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
Enrollment	40 participants
Start Date	2026-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2029-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-31